



























had it won the litigation? and (2) Are the parties sharing monopoly profits preserved by avoiding competition?<sup>8</sup>

**B. *Actavis* rejects the proposition that pharmaceutical patent settlements are generally immune from antitrust scrutiny**

The Supreme Court's rejection of an antitrust immunity premised on the "scope-of-the-patent" approach was unequivocal. A court cannot "answer the

























